We modeled the long‐term cost‐effectiveness following three testing strategies of PCY among GC patients and found that performing PCY testing for potentially curative GC dominated (i.e., less expensive and more effective) non‐testing strategy, through either LPL or PPL. Here, PPL is linked to gastric cancer.